Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 2
1996 1
1998 1
2000 1
2003 1
2004 3
2005 3
2006 3
2007 5
2008 12
2009 4
2010 6
2011 4
2012 2
2013 9
2014 11
2015 3
2016 2
2017 3
2018 6
2019 7
2020 9
2021 12
2022 7
2023 9
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

103 results

Results by year

Filters applied: . Clear all
Page 1
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M; OPTIMISMM trial investigators. Richardson PG, et al. Lancet Oncol. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13. Lancet Oncol. 2019. PMID: 31097405 Clinical Trial.
Eight deaths were related to treatment; six (2%) were recorded in patients who received pomalidomide, bortezomib, and dexamethasone (pneumonia [n=2], unknown cause [n=2], cardiac arrest [n=1], cardiorespiratory arrest [n=1]) and two (1%) were reported …
Eight deaths were related to treatment; six (2%) were recorded in patients who received pomalidomide, bortezomib, and dexamethasone (pneumon …
Caveolae: The FAQs.
Parton RG, Del Pozo MA, Vassilopoulos S, Nabi IR, Le Lay S, Lundmark R, Kenworthy AK, Camus A, Blouin CM, Sessa WC, Lamaze C. Parton RG, et al. Traffic. 2020 Jan;21(1):181-185. doi: 10.1111/tra.12689. Epub 2019 Sep 9. Traffic. 2020. PMID: 31448516 Free PMC article.
The effect of antiretroviral therapyon the periodontal conditions of patients with HIV infection: A systematic review and meta-analysis.
Ntolou P, Pani P, Panis V, Madianos P, Vassilopoulos S. Ntolou P, et al. J Clin Periodontol. 2023 Feb;50(2):170-182. doi: 10.1111/jcpe.13735. Epub 2022 Nov 18. J Clin Periodontol. 2023. PMID: 36261851 Review.

The meta-analysis for NG showed that the overall assessment for the relative frequency ratio in the two groups was 0.45 (n = 7; 95% confidence interval [CI]: [0.21, 0.97]; p < .042). Regarding NP, the overall assessment for the relative frequency ratio in both groups wa

…
The meta-analysis for NG showed that the overall assessment for the relative frequency ratio in the two groups was 0.45 (n = 7; 95% c …
Ixekizumab therapy following secukinumab inadequate response in psoriatic arthritis: a case series focusing on axial disease.
Panagiotopoulos A, Koutsianas C, Kougkas N, Moschou D, Bournia VK, Gazi S, Tektonidou MG, Vassilopoulos D, Sfikakis PP, Fragoulis GE. Panagiotopoulos A, et al. Rheumatol Int. 2023 May;43(5):969-973. doi: 10.1007/s00296-023-05289-3. Epub 2023 Feb 25. Rheumatol Int. 2023. PMID: 36840819
Twenty-four patients (54.2% female, mean [SD] age: 51.6 [14.1]) who were SEC-IR and received IXE either immediately (n = 11) or after 1 interposed biologic disease modifying anti-rheumatic drug (bDMARD) (n = 13) were included. ...For patients with axial involvement …
Twenty-four patients (54.2% female, mean [SD] age: 51.6 [14.1]) who were SEC-IR and received IXE either immediately (n = 11) or after …
103 results